From Guidelines to Clinical Practice: Expert Perspectives on Long‐Term Management of Obesity
Obesity · 2026
DOI: 10.1002/oby.70263 ↗At a glance
Übersichtsarbeit in Obesity, 2026. Written by Hong Chen and 5 co-authors. Institution: Zhujiang Hospital of Southern Medical University, Guangzhou, China. Major MEDLINE topics: Obesity, Anti-Obesity Agents, Practice Guidelines as Topic. 51 references. The full text is freely available (open access, CC BY 4.0). Funded by: Eli Lilly China.
Abstract (original language)
An international panel of experts from the U.S. and China convened to discuss the 2026 TOS–OMA–OAC Expert Guidance Statement on the Pharmacological Management of Obesity, focusing on emerging evidence, regional considerations, and challenges in translating recommendations into long‐term care. Panelists reached a consensus that obesity should be recognized as a chronic and progressive disease, for which pharmacotherapy is lifelong once initiated, as discontinuation consistently leads to weight regain and loss of metabolic benefit. The discussion highlighted a shift toward treating obesity itself as an upstream intervention capable of modifying multiple obesity‐related complications, with greater weight loss generally conferring greater clinical benefit. Visceral adipose tissue emerged as a particularly relevant therapeutic target, especially in Asian populations, where substantial metabolic risk may be present at lower BMI levels. Panelists noted heterogeneity in treatment response and that eventual weight‐loss plateaus should be anticipated as evidence of maximal effectiveness rather than medication failure. The panel endorsed an individualized, stepwise approach integrating pharmacotherapy and metabolic surgery as complementary strategies. Finally, the panel emphasized that translating therapeutic advances into real‐world benefit will require addressing practical barriers related to policy, access, affordability, and stigma to ensure effective care reaches those who need it most.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Zhujiang Hospital of Southern Medical University, Guangzhou, China.
- Zhongda Hospital, Southeast University, Nanjing, China.
- Peking University First Hospital, Beijing, China.
- Division Endocrinology, Diabetes and Metabolic Diseases, Department of Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.
- Division of Endocrinology, Diabetes & Metabolic Diseases, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
- Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
Funding
- Eli Lilly China
Cite
APA
Chen, H., Li, L., Zhang, J., Zhu, S., Cornier, M. A., & Purnell, J. Q. (2026). From Guidelines to Clinical Practice: Expert Perspectives on Long‐Term Management of Obesity. Obesity. https://doi.org/10.1002/oby.70263
Vancouver
Chen H, Li L, Zhang J, Zhu S, Cornier MA, Purnell JQ. From Guidelines to Clinical Practice: Expert Perspectives on Long‐Term Management of Obesity. Obesity. 2026. doi:10.1002/oby.70263
BibTeX
@article{Chen2026,
author = {Chen, Hong and Li, Ling and Zhang, Junqing and Zhu, Shaihong and Cornier, Marc-André and Purnell, Jonathan Q},
title = {From Guidelines to Clinical Practice: Expert Perspectives on Long‐Term Management of Obesity},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70263}
}
EUVIMED